SG Americas Securities LLC Has $23.12 Million Stake in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• SG Americas Securities LLC boosted its stake in Jazz Pharmaceuticals by 2,969.1% in Q4 to 136,024 shares worth $23.12 million, representing 0.22% of the company.
• Jazz beat expectations for the quarter with EPS of $6.64 (vs. $6.49) and revenue of $1.20 billion (vs. $1.17 billion), with revenue up 8.1% year-over-year.
• Research analysts hold a consensus rating of Moderate Buy with an average price target of $215.38, and multiple firms recently upgraded or raised their targets.

SG Americas Securities LLC increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 2,969.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,024 shares of the specialty pharmaceutical company's stock after buying an additional 131,592 shares during the period. SG Americas Securities LLC owned 0.22% of Jazz Pharmaceuticals worth $23,124,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vestal Point Capital LP acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth $127,344,000. Goldentree Asset Management LP acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $149,597,000. Schonfeld Strategic Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 592.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company's stock worth $57,523,000 after purchasing an additional 373,383 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 62.1% in the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company's stock worth $84,341,000 after purchasing an additional 304,463 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after purchasing an additional 298,815 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Truist Financial upgraded Jazz Pharmaceuticals to a "strong-buy" rating in a report on Wednesday. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. TD Cowen reaffirmed a "buy" rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Finally, Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $215.38.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Norbert G. Riedel sold 3,415 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the transaction, the director owned 7,024 shares of the company's stock, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the transaction, the senior vice president owned 28,728 shares of the company's stock, valued at $5,587,308.72. This trade represents a 15.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 68,015 shares of company stock valued at $13,037,486 over the last 90 days. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $189.15 on Friday. The stock's fifty day simple moving average is $175.36 and its 200 day simple moving average is $159.47. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $11.64 billion, a PE ratio of -31.68, a PEG ratio of 0.34 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The company's revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the prior year, the company earned $6.51 earnings per share. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.